Literature DB >> 2599682

The Lexington addicts, 1971-1972: demographic characteristics, drug use patterns, and selected infectious disease experience.

W R Lange1, J C Ball, M B Pfeiffer, F R Snyder, E J Cone.   

Abstract

The demographics, drug habits, and medical complications of a cohort of 1,129 addicts treated at Lexington in the period 1971-1972 were studied. These patients, admitted from 41 different states, had a mean period of addiction of 5.4 years. Over one-third of the sample had engaged in pimping or prostitution, and there were no differences by gender in terms of involvement. Eight-eight percent had shared injection equipment, and surprisingly, 78% admitted to some effort at sterilizing their "works." Hepatitis was the most common associated medical condition: 87% had serologic markers of hepatitis B virus (HBV) infection, 60% had evidence of hepatitis A virus (HAV) exposure, and 47% had abnormal liver function parameters. Gynecomastia was evident in 2% of male subjects. Thirteen percent of the sample had a reactive VDRL assay, but 64% of these were biologically false positive. Subtle abnormalities of immune function were also observed; 18% of the patients had recent unexplained weight loss, 6% had lymphadenopathy, 8% had leukopenia, and 2% had lymphocytopenia. We conclude that both HBV and HAV were important infectious disease risks in these addicts, and that many evidenced deficiencies in immune function well before AIDS became a major public health concern.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2599682     DOI: 10.3109/10826088909047301

Source DB:  PubMed          Journal:  Int J Addict        ISSN: 0020-773X


  2 in total

Review 1.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

2.  Followup study of possible HIV seropositivity among abusers of parenteral drugs in 1971-72.

Authors:  W R Lange; J C Ball; W H Adler; E Brown; R Pyle; W Hoffman; E M Dax
Journal:  Public Health Rep       Date:  1991 Jul-Aug       Impact factor: 2.792

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.